Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission (DAPPI)

Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission (DAPPI)

PI Institution(s)

Principal Investigator (PI)

Partner(s)

Abstract

In the current study, the investigators will assess the efficacy of DP in combination with low-dose PQ to prevent onward malaria transmission. The investigators will perform the investigators study in individuals aged 5-15 years who are carry microscopically detectable densities of P. falciparum gametocytes. This age group is chosen because asexual parasite carriage and gametocyte carriage are common in this age group. All enrolled individuals will receive a full three-day course of DP, and will be randomized to receive a dose of primaquine or placebo with their third dose. Efficacy will be determined based on gametocyte carriage during follow-up, measured by molecular methods. For all individuals, the effect of treatment on infectivity to mosquitoes will be assessed by membrane feeding assays at two time points

http://ClinicalTrials.gov/show/NCT02259426

Key facts

  • Dates
    Oct 2014 to Dec 2015
    Country
    • Kenya

MESA tags

  • Methodology
    Product development & clinical research
    Theme(s)
    Impact of interventions, Tools for elimination